Protein / target
Alpha-1D adrenergic receptor
Protein at a glance
Biological role
Alpha1-adrenergic receptor
Primary biology
GPCR signalling
Strongest disease association
Hypertension
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11).
View complete UniProt function annotationHide complete annotation
Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11). Upon activation, they stimulate the phosphatidylinositol-calcium second messenger pathway, leading to calcium release from intracellular stores and activation of protein kinase C (PubMed:7746284). ADRA1D binds the catecholamine ligands norepinephrine and epinephrine (PubMed:7815325, PubMed:8024574, PubMed:8183249)
Subcellular location
Domains and Gene Ontology detail (13)Hide
Gene Ontology
- Cplasma membrane
- Falpha1-adrenergic receptor activity
- Fidentical protein binding
- Padenylate cyclase-activating adrenergic receptor signaling pathway
- Padenylate cyclase-modulating G protein-coupled receptor signaling pathway
- Pcell-cell signaling
- PG protein-coupled receptor signaling pathway
- Pneuron-glial cell signaling
- Pphospholipase C-activating G protein-coupled receptor signaling pathway
- Ppositive regulation of cell population proliferation
- Ppositive regulation of cytosolic calcium ion concentration
- Ppositive regulation of MAPK cascade
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Cell proliferation & survival
- ·positive regulation of cell population proliferation
G protein-coupled signalling
- ·Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that sig…
- ·adenylate cyclase-modulating G protein-coupled receptor signaling pathway
- ·G protein-coupled receptor signaling pathway
- ·phospholipase C-activating G protein-coupled receptor signaling pathway
View underlying pathways (3)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Broader indication categories (1)Hide
Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.
55 medicines meet Open Targets' target-level approved-medicine definition; the 2 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Adrenergic receptor alpha-1 antagonist
Indicated for Heart Failure, Hypertension, Myocardial Infarction, Ventricular Dysfunction, Left
Adrenergic receptor agonist
Indicated for Angioedema, Asthma, Glaucoma, Heart Arrest
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene ADRA1D
Gene-level evidence surfaced through the gene ADRA1Dthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (4)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
59 compounds recorded · 55 approved · 3 in clinical development · 1 earlier-stage
View all recorded compounds (10)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Emerging
Protein degraders — Emerging
Other modalities — Strong
View underlying tractability evidence (8)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 2 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Regulatory approval
Approval: EPINEPHRINE (ANDA217426)
- Label change
Label change: EPINEPHRINE (NDA204640)
- Product recall
Recall (Class III): EPINEPHRINE
- Regulatory approval
Approval: Eurneffy (EMA)
- New publicationImpact of norepinephrine on immunity and oxidative metabolism in sepsis.
- New publicationMulticenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
- Label change
Label change: EPINEPHRINE (NDA204640)
- Supplemental approval
Supplemental approval: EPINEPHRINE (NDA204640)
- New publicationThe effect of topical epinephrine 1:1000 with and without infiltration of 1% lidocaine with epinephrine 1:100,000 on endoscopic surgical field visualization: a double-blind randomized controlled study.
- Indication expanded
Indication expansion: EPINEPHRINE (NDA204640)
- Regulatory approval
Approval: EPINEPHRINE (NDA204640)
- New publicationThe effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.